A 38-year-old Japanese man had been treated with Fiblast® spray, a product of recombinant human basic fibroblast growth factor, for a skin ulcer after open reduction of a fractured calcaneum. The skin ulcer did not improve well and was associated with desquamative erythema. We observed a positive reaction on patch test against benzalconium chloride, which is included as a preservative in Fiblast® spray. Benzalconium chloride is known to provoke contact dermatitis. We should exercise caution with Fiblast® spray because of its potential to cause contact dermatitis.
ASJC Scopus subject areas